AzurRx BioPharma – Consensus Indicates Potential 286.6% Upside

Broker Ratings

AzurRx BioPharma found using ticker (AZRX) have now 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 7 and 2 with the average target price sitting at 3.75. With the stocks previous close at 0.97 this is indicating there is a potential upside of 286.6%. The day 50 moving average is 0.79 and the 200 day MA is 0.83. The market capitalisation for the company is $27m. You can visit the company’s website by visiting:

AzurRx BioPharma, a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. The company’s therapeutic products are administered to patients as oral non-systemic biologics. Its lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency for cystic fibrosis and chronic pancreatitis patients. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index